SLC5A2 and type 2 diabetes mellitus: To date, there have been six event-driven randomised placebo control trials of SGLT2 inhibition undertaken in T2D populations: the EMPA-REG Outcome trial [2], the CANVAS Program [1] (CANVAS and CANVAS-R), the DECLARE-TIMI58 trial [3], the CREDENCE trial [4], the VERTIS trial [8], and the SCORED trial [7].